Rekah Pharmaceutical Industry Ltd.

TASE:REKA Stock Report

Market Cap: ₪163.6m

Rekah Pharmaceutical Industry Management

Management criteria checks 4/4

Rekah Pharmaceutical Industry's CEO is Mordechai Elgrabli, appointed in Apr 2015, has a tenure of 9.58 years. total yearly compensation is ₪1.01M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 15.32% of the company’s shares, worth ₪25.06M. The average tenure of the management team and the board of directors is 8.5 years and 9.6 years respectively.

Key information

Mordechai Elgrabli

Chief executive officer

₪1.0m

Total compensation

CEO salary percentage100.0%
CEO tenure9.6yrs
CEO ownership15.3%
Management average tenure8.5yrs
Board average tenure9.6yrs

Recent management updates

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

CEO Compensation Analysis

How has Mordechai Elgrabli's remuneration changed compared to Rekah Pharmaceutical Industry's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

₪7m

Mar 31 2024n/an/a

-₪6m

Dec 31 2023₪1m₪1m

-₪7m

Sep 30 2023n/an/a

-₪8m

Jun 30 2023n/an/a

-₪3m

Mar 31 2023n/an/a

-₪2m

Dec 31 2022₪845k₪845k

-₪2m

Sep 30 2022n/an/a

₪4m

Jun 30 2022n/an/a

₪3m

Mar 31 2022n/an/a

₪5m

Dec 31 2021₪830k₪830k

₪7m

Sep 30 2021n/an/a

₪5m

Jun 30 2021n/an/a

₪9m

Mar 31 2021n/an/a

₪10m

Dec 31 2020₪828k₪828k

₪11m

Sep 30 2020n/an/a

₪7m

Jun 30 2020n/an/a

₪5m

Mar 31 2020n/an/a

₪4m

Dec 31 2019₪832k₪832k

₪3m

Sep 30 2019n/an/a

₪6m

Jun 30 2019n/an/a

₪5m

Mar 31 2019n/an/a

₪7m

Dec 31 2018₪801k₪801k

₪8m

Sep 30 2018n/an/a

₪246k

Jun 30 2018n/an/a

-₪8m

Mar 31 2018n/an/a

-₪11m

Dec 31 2017₪795k₪795k

-₪21m

Compensation vs Market: Mordechai's total compensation ($USD277.92K) is below average for companies of similar size in the IL market ($USD427.00K).

Compensation vs Earnings: Mordechai's compensation has been consistent with company performance over the past year.


CEO

Mordechai Elgrabli (80 yo)

9.6yrs

Tenure

₪1,013,000

Compensation

Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...


Leadership Team

NamePositionTenureCompensationOwnership
Mordechai Elgrabli
CEO & Director9.6yrs₪1.01m15.32%
₪ 25.1m
Georgette Elgrabli
Director of Industrial Division & Directorno data₪1.62m15.32%
₪ 25.1m
Jacob Elgrably
Chief Executive Officer of Ophir Shalpharm7.5yrs₪920.00kno data
Nir Sella
Chief Executive Officer - Fresh of Life Pharma Ltd.3.1yrs₪907.00kno data
Meir Melumad
Director of Operationsno data₪684.00kno data
Yuval Elgrabli
Deputy CEO & Director of Business Development13.7yrsno datano data
Yaakov Elgrabli
Chief Executive Officer of Ophir & Shalpharm Ltdno data₪705.00k0.026%
₪ 43.0k

8.5yrs

Average Tenure

67.5yo

Average Age

Experienced Management: REKA's management team is seasoned and experienced (8.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mordechai Elgrabli
CEO & Director31.3yrs₪1.01m15.32%
₪ 25.1m
Georgette Elgrabli
Director of Industrial Division & Director31.3yrs₪1.62m15.32%
₪ 25.1m
Ishay Davidi
Director9.6yrsno datano data
Avraham Bigger
Chairman9.6yrs₪400.00kno data
Orly Zilberman
Independent External Director9.6yrsno datano data
Arnon Zo-Haaretz
Independent External Director8yrsno datano data
Ehud Nissan
Independent External Director8yrsno datano data
Amir Widmann
Directorless than a yearno datano data

9.6yrs

Average Tenure

67.5yo

Average Age

Experienced Board: REKA's board of directors are considered experienced (9.6 years average tenure).